Black Rock Inc. Erasca, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,981,170 shares of ERAS stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,981,170

Previous 7,310,321 4.5%

Holding current value

$16.5 Million

Previous $15.6 Million 7.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.67 - $2.55 $549,682 - $839,335	-329,151 Reduced 4.5%	6,981,170 $14.4 Million
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.49 $472,740 - $704,864	283,078 Added 4.03%	7,310,321 $15.6 Million
Q3 2023 Nov 13, 2023	BUY	$1.97 - $2.91 $216,875 - $320,358	110,089 Added 1.59%	7,027,243 $13.8 Million
Q2 2023 Aug 11, 2023	BUY	$2.57 - $3.3 $3.97 Million - $5.1 Million	1,545,305 Added 28.77%	6,917,154 $19.1 Million
Q1 2023 May 12, 2023	BUY	$2.74 - $4.44 $1.04 Million - $1.68 Million	378,302 Added 7.58%	5,371,849 $16.2 Million

Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $800,383 - $1.76 Million	205,754 Added 4.3%	4,993,547 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $3.12 Million - $5.72 Million	535,420 Added 12.59%	4,787,793 $37.3 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $8.72 $1.84 Million - $3.51 Million	401,963 Added 10.44%	4,252,373 $23.7 Million
Q1 2022 May 12, 2022	BUY	$8.6 - $15.48 $16.9 Million - $30.4 Million	1,961,965 Added 103.89%	3,850,410 $33.1 Million
Q4 2021 Feb 10, 2022	BUY	$12.51 - $22.75 $8.5 Million - $15.5 Million	679,629 Added 56.22%	1,888,445 $29.4 Million
Q3 2021 Nov 09, 2021	BUY	$17.43 - $24.34 $21.1 Million - $29.4 Million	1,208,816 New	1,208,816 $25.7 Million

Others Institutions Holding ERAS

# of Institutions

117

Shares Held

74.3M

Call Options Held

7.1K

Put Options Held

40.1K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $288M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account